Breelyn Wilky tweet-
"CHICAGO — With 38,000 oncologists converging on the sprawling McCormick Place for the annual meeting of the American Society of Clinical Oncology, the halls in the convention center are as crowded as Manhattan sidewalks at Christmastime. Watch out or you'll get run over as attendees rush to the next meeting of the minds.
The conference, which opened Friday and wraps up Tuesday, features hundreds of sessions and poster presentations ranging from the highly technical (“Predictive biomarkers of ipilimumab toxicity in metastatic melanoma”) to tips for everyday practice (“Patient communication: Balancing hope versus reality"). While most of the topics are as serious as, well, cancer, there are some lighter moments. Here's a look at a few things that have been getting play:"
https://www.washingtonpost.com/news/to- ... e1bd963ee
8 things doctors are buzzing about at the biggest cancer meeting
8 things doctors are buzzing about at the biggest cancer meeting
Last edited by D.ap on Mon Jun 12, 2017 5:00 am, edited 1 time in total.
Debbie
Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report"
Link within above article
"Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report"
https://endpts.com/checkpoint-combos-fo ... es-report/
"Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report"
https://endpts.com/checkpoint-combos-fo ... es-report/
Last edited by D.ap on Mon Jun 12, 2017 4:56 am, edited 2 times in total.
Debbie
Re: 8 things doctors are buzzing about at the biggest cancer meeting
About 11th paragraph down in main link
"Location, location, location — but maybe less for tumors: Recently, the FDA approved a Merck cancer drug for any type of malignancy, as long as the tumor tested positive for a specific genetic defect. At the meeting here, Loxo Oncology presented results that showed a drug called larotrectinib shrank tumors in 17 different cancers with a defect called a TRK fusion. The company plans to use the findings and other data to seek FDA approval for the therapy.
If larotrectinib gets the nod, it will be another step toward basing treatments on genetic characteristics rather than the parts of the body where tumors originate."
"Location, location, location — but maybe less for tumors: Recently, the FDA approved a Merck cancer drug for any type of malignancy, as long as the tumor tested positive for a specific genetic defect. At the meeting here, Loxo Oncology presented results that showed a drug called larotrectinib shrank tumors in 17 different cancers with a defect called a TRK fusion. The company plans to use the findings and other data to seek FDA approval for the therapy.
If larotrectinib gets the nod, it will be another step toward basing treatments on genetic characteristics rather than the parts of the body where tumors originate."
Debbie